NeuroSense Therapeutics Ltd. NRSN
6.95
(0.45)
(6.08%)
as of 25 Sep
- Market cap
- $14.0M
- P/E
- 0.0×
Follow NRSN
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Mar '24 | Jun '24 | Sep '24 | Jun '25 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
705.26% | 0.00% | 0.00% | 0.00% | |
| (426.84%) | 0.00% | 0.00% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
444.61% | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | — | 0.00 | |
Free Cash Flow |
— | (15.73) | — | (18.18) | |
Capital Expenditures |
— | (0.07) | — | (0.06) | |
| Other line items | |||||
Cash ROIC |
0.00% | 3,691.75% | 0.00% | (9,533.68%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
0.00% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | — | — | — | |
Share Based Compensation of Revenue |
— | — | — | 0.00% | |
Interest Coverage |
0.00 | — | — | — | |
Operating CF/Net income |
0.00 | 0.00 | — | 0.00 | |
Depreciation/Fixed assets |
0.00 | 1.32 | 0.00 | 1.70 | |
Capex/Depreciation |
— | (0.74) | — | (0.59) | |
Revenue per Share |
0.00 | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | — | 0.00 | |
Capex per Share |
0.00 | 0.00 | — | 0.00 | |
Capex to Sales |
— | 0.00 | — | 0.00 | |
Net Profit Margin |
0.00% | — | — | — |
Columns are period end dates